6 September 2019
SpeeDx Receives CE-IVD Clearance for ResistancePlus® MG FleXible
ResistancePlus® MG FleXible for the Cepheid GeneXpert® System is now CE-IVD and available for sale in Europe. The test detects...
21 August 2019
Grant Awarded to University Collaboration with SpeeDx
The Australian Research Council (ARC) awarded almost $5 million to a collaboration with SpeeDx and over 20 other organisations, for...
8 August 2019
SpeeDx collaborate on test for premature birth risk
Researchers at The University of Western Australia and King Edward Memorial Hospital have teamed up with SpeeDx to commercialise a...
6 August 2019
SpeeDx Raise US $15 million Equity from Northpond Ventures
Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets....
16 July 2019
Health Canada clears ResistancePlus® MG
This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy...
24 June 2019
SpeeDx sign collaboration agreement with GSK
SpeeDx signed a collaboration agreement with GSK to provide tests and custom test development to support antibiotic clinical trials...
